Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Irving

Showing results (51-60 of 194) with videos related to

Pageof 20
Sort By:
BMJ Open Gastroenterology|February 18, 2021
Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort studyPeter M Irving, Simon de Lusignan, Daniel Tang, et al.
The Proceedings of the Nutrition Society|June 21, 2017
The challenges of control groups, placebos and blinding in clinical trials of dietary interventionsHeidi M Staudacher, Peter M Irving, Miranda C E Lomer, et al.
Inflammatory Bowel Diseases|September 18, 2020
Tofacitinib for the Treatment of Ulcerative Colitis, Alopecia Universalis, and Atopic Dermatitis: One Drug, Three DiseasesSailish Honap, Hannah Cookson, Esha Sharma, et al.
Nature Reviews. Gastroenterology & Hepatology|March 8, 2018
Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to managementMark A Samaan, Polychronis Pavlidis, Sophie Papa, et al.
The Proceedings of the Nutrition Society|September 1, 2017
The challenges of control groups, placebos and blinding in clinical trials of dietary interventionsHeidi M Staudacher, Peter M Irving, Miranda C E Lomer, et al.
European Journal of Gastroenterology & Hepatology|July 29, 2009
Benefits of breath hydrogen testing after lactulose administration in analysing carbohydrate malabsorptionJohn P Bate, Peter M Irving, Jacqueline S Barrett, et al.
Frontline Gastroenterology|August 26, 2017
Steroids in villous atrophy: opening a can of worms?Lennard Lee, Paul Blaker, Baljit Gill, et al.
European Journal of Gastroenterology & Hepatology|February 8, 2006
Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinicsJoel E D Mawdsley, Peter M Irving, Richard J Makins, et al.
F1000Research|August 27, 2019
Biologic therapies for Crohn's disease: optimising the old and maximising the newMark Samaan, Samantha Campbell, Georgina Cunningham, et al.
Gut|January 26, 2020
Regulatory T-cell therapy in Crohn's disease: challenges and advancesJennie N Clough, Omer S Omer, Scott Tasker, et al.
Pageof 20

Showing results (51-60 of 194) with videos related to

Sort By:
Pageof 20
BMJ Open Gastroenterology|February 18, 2021
Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort studyPeter M Irving, Simon de Lusignan, Daniel Tang, et al.
The Proceedings of the Nutrition Society|June 21, 2017
The challenges of control groups, placebos and blinding in clinical trials of dietary interventionsHeidi M Staudacher, Peter M Irving, Miranda C E Lomer, et al.
Inflammatory Bowel Diseases|September 18, 2020
Tofacitinib for the Treatment of Ulcerative Colitis, Alopecia Universalis, and Atopic Dermatitis: One Drug, Three DiseasesSailish Honap, Hannah Cookson, Esha Sharma, et al.
Nature Reviews. Gastroenterology & Hepatology|March 8, 2018
Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to managementMark A Samaan, Polychronis Pavlidis, Sophie Papa, et al.
The Proceedings of the Nutrition Society|September 1, 2017
The challenges of control groups, placebos and blinding in clinical trials of dietary interventionsHeidi M Staudacher, Peter M Irving, Miranda C E Lomer, et al.
European Journal of Gastroenterology & Hepatology|July 29, 2009
Benefits of breath hydrogen testing after lactulose administration in analysing carbohydrate malabsorptionJohn P Bate, Peter M Irving, Jacqueline S Barrett, et al.
Frontline Gastroenterology|August 26, 2017
Steroids in villous atrophy: opening a can of worms?Lennard Lee, Paul Blaker, Baljit Gill, et al.
European Journal of Gastroenterology & Hepatology|February 8, 2006
Optimizing quality of outpatient care for patients with inflammatory bowel disease: the importance of specialist clinicsJoel E D Mawdsley, Peter M Irving, Richard J Makins, et al.
F1000Research|August 27, 2019
Biologic therapies for Crohn's disease: optimising the old and maximising the newMark Samaan, Samantha Campbell, Georgina Cunningham, et al.
Gut|January 26, 2020
Regulatory T-cell therapy in Crohn's disease: challenges and advancesJennie N Clough, Omer S Omer, Scott Tasker, et al.
Pageof 20